Antimuscarinic delirium (AMD) is a common and dangerous toxicology condition caused by poisoning by medications and other chemicals that block muscarinic receptors. Physostigmine, the standard antidote for AMD, currently has very limited availability in the United States due to an interruption of production.
Recent case reports and small observational studies suggest that rivastigmine might be useful in the treatment of AMD, but there is not direct prospective evidence comparing rivastigmine to physostigmine or supportive care. In order to investigate the effectiveness of rivastigmine, the investigators propose a randomized, placebo-controlled clinical trial of rivastigmine for AMD. The investigators hypothesize that patients treated with rivastigmine for antimuscarinic delirium will experience more rapid resolution of agitation and delirium than those treated with placebo.

Start Date01 Nov 2025

Sponsor / Collaborator

Washington University School of Medicine

[+1]

NCT06399679

/ RecruitingPhase 2IIT

Rivastigmine to Prevent Recurrence of Antimuscarinic Delirium After Initial Control With Physostigmine (RIVA-AP): a Randomized, Placebo-controlled Trial

Antimuscarinic delirium (AMD) is a common and dangerous toxicology condition caused by poisoning by medications and other chemicals that block muscarinic receptors. Physostigmine is effective in reversing AMD but has a short duration of action, and patient commonly experience recurrence of AMD after initial control with physostigmine.
Recent case reports and small observational studies suggest that rivastigmine, which has a longer duration of action than physostigmine, might be useful in the treatment of AMD. In order to investigate the effectiveness of rivastigmine in preventing recurrence of AMD after initial control with physostigmine, the investigators propose a randomized, placebo-controlled clinical trial of rivastigmine for AMD. The investigators hypothesize that patients treated with rivastigmine after initial control of AMD with physostigmine will experience less recurrence of antimuscarinic delirium than those treated with placebo.

Start Date04 Nov 2024

Sponsor / Collaborator

Washington University School of Medicine

[+1]

IRCT20130719014054N3

/ RecruitingPhase 3IIT

A randomized clinical trial study on the safety and efficacy of rivastigmine on cognitive function in HIV infected patients

Start Date05 Aug 2024

Sponsor / Collaborator

Tehran University of Medical Sciences

100 Clinical Results associated with Rivastigmine Tartrate

100 Translational Medicine associated with Rivastigmine Tartrate

100 Patents (Medical) associated with Rivastigmine Tartrate

2,153

Literatures (Medical) associated with Rivastigmine Tartrate

01 Feb 2025·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Discovery of novel hybrid tryptamine-rivastigmine molecules as potent AChE and BChE inhibitors exhibiting multifunctional properties for the management of Alzheimer's disease

Article

Author: Kumar, Prabhat ; Shankar, Gauri ; Ghosh, Aparajita ; Kulkarni, Onkar ; Modi, Gyan ; Garg, Prabha ; Srikrishna, Saripella ; Wani, Mushtaq Ahmad ; Kumar, Sunil ; Kumar, Saroj ; Mandloi, Upesh ; Rai, Sanskriti ; Varma, Tanmaykumar ; Singh, Gireesh Kumar

Contemporary research evidence has corroborated a gradual loss of central cholinergic neurons in Alzheimer's Disease (AD). This progressive deterioration leads to cognitive dysfunction and impaired motor activity, culminating in the brain cell's death in the disease. The approved drugs for AD treatment can only offer relief from symptoms without addressing the underlying pathological hallmarks of the disease. To address the limitations associated with rivastigmine (RIV), a marketed drug for AD, a series of tryptamine derivatives was designed, synthesized, and evaluated in various in-vitro and in-vivo AD models. Enzyme inhibition studies identified compounds 6d and 6e as the lead molecules with potent inhibitors against AChE (6d, IC₅₀: 0.99 ± 0.009 nM and 6e IC₅₀: 7.97 ± 0.016 nM and BChE (6d, IC₅₀: 27.79 ± 0.21 nM and 6e, IC₅₀: 0.79 ± 0.005 nM), compared to the marketed drug Riv (AChE, IC₅₀: 6630 ± 0.76 nM, BChE IC₅₀ = 91 ± 0.40 nM). The molecular docking and dynamics studies corroborated the enzyme inhibition studies. The PAMPA assay strongly suggested the BBB crossing ability of the lead molecules. Further, 6d and 6e demonstrated the capability to counteract oxidative stress and Aβ_1-42 in various in-vitro studies. Compound 6e exhibited remarkable radical scavenging activity in the DPPH assay (IC₅₀: 22.91 ± 1.73 μM) compared to rivastigmine (% radical scavenging activity: 3.71 ± 0.09 at 200 μM). Interestingly, 6d and 6e exhibited promising activity in the AD Drosophila model by protecting eye phenotypes from degeneration induced by Aβ_1-42 toxicity and reduced mitochondrial and cellular oxidative stress in this model. Furthermore, upon oral administration, 6d and 6e could reverse scopolamine-induced amnesia by improving spatial and cognitive memory in mice at 0.3 and 0.5 mg/kg compared to rivastigmine at 3 mg/kg and were found to have potent ex-vivo anti-ChEs properties, which are correlated with the observed pro-cognitive effects in the Morris Water Maze, likely mediated through the inhibition of both cholinesterases. The expression of various neuroprotection markers, such as BDNF and TRKB, was significantly overexpressed compared to the disease control group.

01 Feb 2025·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Design, synthesis and biological evaluation of new H2S-releasing rivastigmine derivatives as neuroprotective molecules

Article

Author: Sestito, Simona ; Raffellini, Lorenzo ; Calderone, Vincenzo ; Martini, Claudia ; Citi, Valentina ; Martelli, Alma ; La Rocca, Veronica ; Daniele, Simona ; Rapposelli, Simona ; Sagona, Simona ; Manera, Clementina ; Cirone, Italo ; Lai, Michele ; Runfola, Massimiliano

Alzheimer's disease (AD) represents one of the main challenges for the 21st century medical research as no disease-modifying agent has been successfully progressed to the market, while the number of people affected by AD is estimated to grow exponentially over the next years. The complex network of triggering factors involved in the insurgence and progression of AD can be rightly addressed as one of the main reasons behind the difficulty in identifying new pharmacological approaches. For this reason, the discovery and development of drugs endowed with pleiotropic activity remain the most valuable, but at the same time challenging, approaches to tackle down AD. Interestingly, the combination of active pharmacophores through molecular hybridization - or Multi-Target Directed Ligand strategy (MTDL) - has not been explored enough for this disease, despite proving to be a successfully strategy in other field, such as oncology. To contribute to the development of new strategies against AD, we decided to explore the hybridization of the marketed drug rivastigmine - prescribed to ameliorate AD symptomatology - with moieties capable to release hydrogen sulfide (H₂S), a gasotransmitter with a key role in the neurological physiology of ageing. In particular, we identified compound 1, as a potent small molecule capable of inhibit AChE, preventing inflammation and ROS production in cultured neurons and microglia, triggering autophagy response and blocking Aβ fibrils propagation. Interestingly, the beneficial effects observed in vitro have been confirmed in vivo, since the rivastigmine derivative 1 improved the lifespan in a Caenorhabditis elegans model of AD.

01 Jan 2025·JOURNAL OF INORGANIC BIOCHEMISTRY

Exploiting the potential of rivastigmine-melatonin derivatives as multitarget metal-modulating drugs for neurodegenerative diseases

Article

Author: Bon, Leo ; Dias, Inês ; Guerreiro-Oliveira, Catarina ; Sanna, Daniele ; Borges, Fernanda ; Santos, M. Amélia ; Cardoso, Sandra M ; Chavarria, Daniel ; Cardoso, Sandra M. ; Chaves, Sílvia ; Garribba, Eugenio ; Banas, Angelika ; Banas`, Angelika ; Santos, M Amélia

The multifaceted nature of the neurodegenerative diseases, as Alzheimer's disease (AD) and Parkinson's disease (PD) with several interconnected etiologies, and the absence of effective drugs, led herein to the development and study of a series of multi-target directed ligands (MTDLs). The developed RIV-IND hybrids, derived from the conjugation of an approved anti-AD drug, rivastigmine (RIV), with melatonin analogues, namely indole (IND) derivatives, revealed multifunctional properties, by associating the cholinesterase inhibition of the RIV drug with antioxidant activity, biometal (Cu(II), Zn(II), Fe(III)) chelation properties, inhibition of amyloid-β (Aβ) aggregation (self- and Cu-induced) and of monoamine oxidases (MAOs), as well as neuroprotection capacity in cell models of AD and PD. In particular, two hybrids with hydroxyl-substituted indoles (5a2 and 5a3) could be promising multifunctional compounds that inspire further development of novel anti-neurodegenerative drugs.

News (Medical) associated with Rivastigmine Tartrate

16 Dec 2024

·www.alphacognition.com

Alpha Cognition Announces Partial Exercise of Over-Allotment Option

VANCOUVER, British Columbia and Dallas, TX — December 16, 2024 (BUSINESS WIRE) — Alpha Cognition Inc. (Nasdaq: ACOG) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced that the underwriters of its underwritten U.S. public offering (the “Offering”) have partially exercised their over-allotment option to purchase an additional 488,506 common shares at the public offering price of US$5.75 per share for an additional US$2.8 million in gross proceeds. After giving effect to the partial exercise of the over-allotment option, the Company sold an aggregate 9,184,159 common shares for gross proceeds of approximately US$52.8 million, before deducting underwriter discounts and other related expenses. The option closing date was December 16, 2024. The common shares began trading on The Nasdaq Capital Market on November 12, 2024, under the ticker symbol “ACOG”. The Company intends to use the proceeds towards the commercialization and launch of ZUNVEYLTM in Alzheimer’s Disease, further research and development of its pipeline product candidates, continued commercial CMC activities (chemistry, manufacturing, and controls), and for working capital and general corporate purposes. Titan Partners Group, a division of American Capital Partners, is acting as Sole Bookrunner for the offering. The securities were sold pursuant to a registration statement on Form S-1 (File No. 333-280196) relating to these securities and a related registration statement on Form S-1 MEF that became effective upon its filing in accordance with Rule 462(b) under the Securities Act of 1933, as amended. The Offering is being made only by means of a prospectus. A copy of the final prospectus related to the Offering may be obtained from Titan Partners Group LLC, a division of American Capital Partners, LLC, 4 World Trade Center, 29th Floor, New York, NY 10007, or via email at prospectus@titanpartnersgrp.com or telephone at (929) 833-1246. In addition, a copy of the final prospectus relating to the Offering may be obtained via the SEC's website at www.sec.gov. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it improves the function of neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. Benzgalantamine is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. Forward-looking Statements This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the potential use of proceeds of the Offering. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future. Contacts For further information: Michael McFadden, CEO Tel: 1-858-344-4375 info@alphacognition.com Titan Partners Contact: Tel: (929) 833-1246 info@titanpartnersgrp.com.

Clinical Study

12 Dec 2024

·www.businesswire.com

Alpha Cognition Announces Voluntary Delisting from CSE

VANCOUVER, British Columbia & DALLAS--( BUSINESS WIRE )-- Alpha Cognition Inc. (NASDAQ: ACOG) (“Alpha Cognition”, or the “Company”), announces that in connection with the Company’s listing on the Nasdaq Capital Market the Company will voluntarily delist its common shares from the Canadian Securities Exchange. The shares will be delisted from the Canadian Securities Exchange at the close of trading on December 17, 2024. The Company’s common shares will continue to trade on the Nasdaq under the symbol “ACOG”. About Alpha Cognition Inc. Alpha Cognition Inc. is a commercial stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ZUNVEYL is a patented drug approved as a new generation acetylcholinesterase inhibitor (AChEI) for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ZUNVEYL’s active metabolite is differentiated from donepezil and rivastigmine in that it improves the function of neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. Benzgalantamine is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia, and as an intranasal formulation for Cognitive Impairment with mTBI. Forward-looking Statements: This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future.

Drug Approval

11 Dec 2024

·www.businesswire.com

Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury

VANCOUVER, British Columbia & DALLAS--( BUSINESS WIRE )--Alpha Cognition Inc. (Nasdaq: ACOG) (CSE: ACOG) (“Alpha Cognition” [ACI], or the “Company”), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced interim preclinical data that supports the continued development of ALPHA-1062 for the treatment of mild traumatic brain injury (mTBI). The interim data provides evidence of benefit for ALPHA-1062, in the treatment of mTBI resulting from repetitive blast trauma, a highly relevant military injury. Blast caused mTBI is considered to be the signature injury effecting soldiers where brain injury from explosive devices and artillery fire blast exposure is highly prevalent. ACI previously documented extensive functional and neuropathological protection, provided by ALPHA-1062 administration, following a single moderate traumatic brain injury. This second pre-clinical study in a rodent model, supported by the US Department of Defense (DOD), is a collaboration with investigators at the Seattle Institute of Biomedical and Clinical Research (affiliated with both the University of Washington and the Veterans Administration). The study is ongoing, with interim data demonstrating that ALPHA-1062 administration following 3 consecutive days of blast induced mTBI, results in a reduction of TBI associated neuropathology. Key findings demonstrated that, ALPHA-1062 administration reduced levels of neuroinflammation markers and neuropathology that occurs after blast trauma. High dose ALPHA-1062 reduced the levels of myeloid cell activation [CD 68] across multiple brain regions one month after blast. High dose ALPHA-1062 also demonstrated the ability to reduce midbrain astrogliosis [GFAP]. Astrogliosis is a process where brain cells called astrocytes become larger, multiply, and change in response to injury or disease in the brain. “These outcomes indicate a protective effect of ALPHA-1062, and demonstrated a reduction of neuropathology. The data provide further support for the continued development of ALPHA-1062 for the treatment of acute mild traumatic brain injury,” said Denis Kay, ACI’s Chief Scientific Officer. Further analysis of neuropathology and neurobehavioral [functional recovery] data is ongoing with the final study report due Q2/2025. About Alpha Cognition Inc. Alpha Cognition Inc. is a clinical stage, biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer’s disease and Cognitive Impairment with mild Traumatic Brain Injury (“mTBI”), for which there are currently no approved treatment options. ALPHA-1062, is a patented new chemical entity being developed as a new generation acetylcholinesterase inhibitor for the treatment of Alzheimer’s disease, with expected minimal gastrointestinal side effects. ALPHA-1062’s active metabolite is differentiated from donepezil and rivastigmine in that it binds neuronal nicotinic receptors, most notably the alpha-7 subtype, which is known to have a positive effect on cognition. ALPHA-1062 is also being developed in combination with memantine to treat moderate to severe Alzheimer’s dementia. An intranasal formulation of ALPHA-1062 has demonstrated potent preservation brain structure and function in a preclinical model of moderate TBI, where enhanced recovery from the brain injury was also seen. The intranasal formulation is currently being evaluated for its ability to provide protection from a military relevant model of repeated mild TBI, in a program sponsored by the US Department of Defense. Neither Canadian Securities Exchange (the “CSE”) or the OTC Markets Group, accepts responsibility for the adequacy or accuracy of this release. Forward-looking Statements This news release includes forward-looking statements within the meaning of applicable securities laws. Except for statements of historical fact, any information contained in this news release may be a forward‐looking statement that reflects the Company’s current views about future events and are subject to known and unknown risks, uncertainties, assumptions and other factors that may cause the actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words “may,” “might,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “objective,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “contemplate,” “continue” and “ongoing,” or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the TBI out-licensing plan and associated financing, the availability of funding pursuant to financings, the Company’s business strategy, market size, potential growth opportunities, capital requirements, clinical development activities, the timing and results of clinical trials, regulatory submissions, potential regulatory approval and commercialization of the Company’s products. Although the Company believes to have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. The Company cannot assure that the actual results will be consistent with these forward-looking statements. These forward‐looking statements speak only as of the date of this news release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future.

100 Deals associated with Rivastigmine Tartrate

External Link

KEGG	Wiki	ATC	Drug Bank
D02558	Rivastigmine Tartrate	N06DA03	DB00989

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Progressive Supranuclear Palsy Atypical	US	Sandoz, Inc.	06 Jul 2007
Parkinson Disease	US	Novartis Pharmaceuticals Corp.	27 Jun 2006
Alzheimer Disease	US	Novartis Pharmaceuticals Corp.	21 Apr 2000
Dementia	US	Novartis Pharmaceuticals Corp.	21 Apr 2000
Dementia due to Alzheimer's disease (disorder)	EU	Novartis Europharm Ltd.	11 May 1998
Dementia due to Alzheimer's disease (disorder)	IS	Novartis Europharm Ltd.	11 May 1998
Dementia due to Alzheimer's disease (disorder)	LI	Novartis Europharm Ltd.	11 May 1998
Dementia due to Alzheimer's disease (disorder)	NO	Novartis Europharm Ltd.	11 May 1998
Dementia due to Parkinson's disease	EU	Novartis Europharm Ltd.	11 May 1998
Dementia due to Parkinson's disease	IS	Novartis Europharm Ltd.	11 May 1998
Dementia due to Parkinson's disease	LI	Novartis Europharm Ltd.	11 May 1998
Dementia due to Parkinson's disease	NO	Novartis Europharm Ltd.	11 May 1998

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Delirium	Phase 3	FR	Novartis Pharmaceuticals Corp.	01 Jun 2011
Emergence Delirium	Phase 3	CH	Novartis AG	01 Jan 2006
Neurobehavioral Manifestations	Phase 3	-	Novartis AG	01 Jan 2003
Brain Injuries, Traumatic	Phase 3	-	Novartis AG	01 Nov 2002
Cognitive Dysfunction	Phase 3	-	Novartis AG	01 Nov 2002
Dementia, Vascular	Phase 3	US	Novartis Pharmaceuticals Corp.	01 Aug 2001
Dementia, Vascular	Phase 3	AT	Novartis Pharmaceuticals Corp.	01 Aug 2001
Dementia, Vascular	Phase 3	CA	Novartis Pharmaceuticals Corp.	01 Aug 2001
Dementia, Vascular	Phase 3	FR	Novartis Pharmaceuticals Corp.	01 Aug 2001
Dementia, Vascular	Phase 3	DE	Novartis Pharmaceuticals Corp.	01 Aug 2001

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02989402 (CTgov)	Phase 4	Dementia due to Alzheimer's disease (disorder)	100	Rivastigmine	xjseddliqd(lqedcjjztz) = ltzrwppuir vnmgloeldp (nflolhtthw, oexyqhaqmr - fqnbqcegfr) View more	-	31 May 2024
UEGW2022	Not Applicable	-	-	Single intragastric dose of 6 mg rivastigmine hydrogen tartrate	dkygunjilh(bgigyopgkh) = msycqhwbgr zprcicaptk (hhqanwlnmj, 736.5 - 2330)	-	09 Oct 2022
				Repeated intragastric administration of rivastigmine hydrogen tartrate for 7 days (6 mg per day)	dkygunjilh(bgigyopgkh) = lazyyswhwk zprcicaptk (hhqanwlnmj, 549 - 5093) View more
NCT03915626 (CTgov)	Early Phase 1	-	7	Rivastigmine (RLD) transdermal patch (RLD Patch)	sermmwrxie(rwurjgqgmz) = vtotplmzjz sitvqeauvl (tynljuzvma, kqfujwfrbq - fkwdctgqoe) View more	-	07 Mar 2022
				Rivastigmine (generic) transdermal patch (Generic Patch)	sermmwrxie(rwurjgqgmz) = akrwybvrvu sitvqeauvl (tynljuzvma, ikvblvqzgr - ntkhnferoa) View more
NCT01340885 (CTgov)	Phase 4	Cognitive Dysfunction \| Parkinson Disease	9	Strattera (Atomoxetine)	mflmpixhor(ipjxuyvgen) = vgblnmipqj bkpkgoifcg (aalopuhwvy, tqbkooflur - qyxwhdrnpa) View more	-	07 Jul 2020
				Exelon (Rivastigimine)	mflmpixhor(ipjxuyvgen) = bckxahbvpi bkpkgoifcg (aalopuhwvy, imnvpupena - itznprxuoa) View more
NCT02703636 (ENA1stepswitch, CTgov)	Phase 4	Alzheimer Disease	118	Rivastigmine Patch	lwwrxhcdgy(rsukdynblo) = niznmgycrt sblpzeqklf (rbicinynsr, xgiypqlrmq - tdnsyiarvc) View more	-	12 Sep 2019
NCT02703636 (ENA1stepswitch, Pubmed) Manual	Phase 4	Alzheimer Disease	102	Rivastigmine	jyultoibhe(tqgipvkldr) = a least-square mean change (SD) of -0.35 (2.64) vrkkgsyklc (qfrkaglhxz )	Positive	15 Aug 2019
NCT01380288 (Pubmed \| J Biol Chem \| PLoS One) Manual	Not Applicable	Alzheimer Disease \| Leukoencephalopathies	300	rivastigmine (with minimal WMHs)	bsuqkeqpbs(gapcmqjmxi) = rrfwslqrgv niqcqfcqmc (nxwfzgdkil, 5.70) View more	Positive	07 Aug 2017
				rivastigmine (with moderate WMHs)	bsuqkeqpbs(gapcmqjmxi) = roczccnxus niqcqfcqmc (nxwfzgdkil, 5.98) View more
NCT01670526 (RIVET, CTgov)	Phase 3	Cognitive Dysfunction \| Brain Injuries, Traumatic	94	Rivastigmine Transdermal Patch (Rivastigmine)	dctldrvkrs(ahpqtbaxim) = ivtmwdxcxk msrteqsdjd (jxndsspsld, rsmqpfotvj - istnshxmxo) View more	-	25 Jul 2017
				Rivastigmine Transdermal Patch (Placebo)	dctldrvkrs(ahpqtbaxim) = imhoxxgxgt msrteqsdjd (jxndsspsld, tidlqdezqq - aaaxbbssre) View more
NCT01602198 (CTgov)	Not Applicable	Mild cognitive disorder	1	Exelon [rivastigmine] transdermal patch (Exelon Transdermal Patch)	uiybtboztg(qhyktadivf) = dfqlmmhgal nexlvkkcrg (nryegcwcld, asetmxnixr - rxjlmpnsmj) View more	-	28 Feb 2017
				Placebo transdermal patch (Placebo Transdermal Patch)	uiybtboztg(qhyktadivf) = ltlixbyier nexlvkkcrg (nryegcwcld, wvarrdpijl - fjnxndrcar) View more
NCT01362686 (COMET-AD, CTgov)	Not Applicable	Alzheimer Disease	200	Donepezil (Donepezil)	wesbzwhiis(pfgunupssl) = rchxuvtsgf wrxuqgpqyk (qdxejrtxcc, wjtfgepkbz - cqtntpdbqb) View more	-	27 Feb 2017
				Galantamine (Galantamine)	wesbzwhiis(pfgunupssl) = zgiacnfjst wrxuqgpqyk (qdxejrtxcc, nhybgontzu - uksskhuovd) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis